Construction of an Excellent 7 mRNAsi-Related Gene Model Based on Cancer Stem Cells for Predicting Survival Outcome of Cervical Cancer

Background. Cervical cancer (CC) is one of the most frequent female malignancy. Cancer stem cells (CSCs) positively affect survival outcomes in cancer patients, but in cervical cancer, the mechanism of tumor stem cells is still uncertain. Methods. RNA-seq data and related clinical follow-up of patients suffering from CC were from TCGA. Consensus clustering screened prognostic mRNAsi-related genes and identified molecular subtypes for CC. Based on the overlapping differentially expressed genes (DEGs) in subtypes, we employed LASSO and multivariate Cox regression to screen prognostic-related genes and established the RiskScore system. The patients were grouped by RiskScore, the prognosis was analyzed by the Kaplan-Meier (K-M) curve among the various groups, and the precision of the RiskScore was assessed by the ROC curve. Finally, the potential worth of RiskScore in immunotherapy/chemotherapy response was assessed by evaluating TIDE scores and chemotherapy drug IC 50 values. Results. We noticed that patients with low mRNAsi had a shorter survival and then identified three molecular subtypes (C1-3), with the C1 having the worst prognosis and the lowest mRNAsi. Finally, we identified 7 prognostic-related genes (SPRY4, PPP1R14A, MT1A, DES, SEZ6L2, SLC22A3, and CXCL8) via LASSO and Cox regression analysis. We established a 7-gene model defined RiskScore to predict the prognosis of CC patients. K-M curve indicated that low RiskScore patients had improved prognosis, and ROC curves indicated that RiskScore could precisely direct the prognostic evaluation for those suffering from the cancer. This was also confirmed in the GSE44001 and GSE52903 external cohorts. Patients were more sensitive to immunotherapy if with low RiskScore, and RiskScore exhibited precise assessment ability in predicting response to immunological therapy in CC patients. Conclusion. CC stemness is associated with patient prognosis, and the RiskScore constructed based on stemness characteristics is an independent prognostic index, which is expected to be a guide for immunotherapy, providing a new idea for CC clinical practice.

[1]  Cheng Sun,et al.  Establishment of a cell senescence related prognostic model for predicting prognosis in glioblastoma , 2022, Frontiers in Pharmacology.

[2]  Youzhong Zhang,et al.  Blocking TIGIT/CD155 signalling reverses CD8+ T cell exhaustion and enhances the antitumor activity in cervical cancer , 2022, Journal of translational medicine.

[3]  Yang Li,et al.  SEZ6L2, regulated by USF1, accelerates the growth and metastasis of breast cancer. , 2022, Experimental cell research.

[4]  Yuanyuan Ruan,et al.  Stemness-related LncRNA pair signature for predicting therapy response in gastric cancer , 2021, BMC Cancer.

[5]  N. Almog,et al.  Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. , 2021, Cancer cell.

[6]  Kun Yu,et al.  SPRY4 suppresses proliferation and induces apoptosis of colorectal cancer cells by repressing oncogene EZH2 , 2021, Aging.

[7]  A. Santin,et al.  Immunotherapy in Cervical Cancer , 2021, Current Oncology Reports.

[8]  Lu Gao,et al.  Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients , 2021, Briefings Bioinform..

[9]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[10]  Tracey F Lee-Pullen,et al.  PD‐L1+ dendritic cells in the tumor microenvironment correlate with good prognosis and CD8+ T cell infiltration in colon cancer , 2020, Cancer science.

[11]  H. Nijman,et al.  Tumor-infiltrating lymphocytes in the immunotherapy era , 2020, Cellular & Molecular Immunology.

[12]  Y. Jing,et al.  Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer , 2020, British Journal of Cancer.

[13]  Tsuyoshi Saito,et al.  Association between cancer immunity and treatment results in uterine cervical cancer patients treated with radiotherapy. , 2020, Japanese journal of clinical oncology.

[14]  Weijian Guo,et al.  Tumor purity as a prognosis and immunotherapy relevant feature in gastric cancer , 2020, Cancer medicine.

[15]  A. Jemal,et al.  Factors associated with advanced stage at diagnosis of cervical cancer in Addis Ababa, Ethiopia: a population-based study , 2020, BMJ Open.

[16]  G. Petroni,et al.  Results of an early safety analysis of a study of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer , 2020, Cancer.

[17]  J. Duanmu,et al.  Analyzing and validating the prognostic value and mechanism of colon cancer immune microenvironment , 2020, Journal of Translational Medicine.

[18]  Zitong Zhao,et al.  Integrative Bioinformatics Approaches to Screen Potential Prognostic Immune-Related Genes and Drugs in the Cervical Cancer Microenvironment , 2020, Frontiers in Genetics.

[19]  D. Parkin,et al.  Cervical cancer survival in sub‐Saharan Africa by age, stage at diagnosis and Human Development Index: A population‐based registry study , 2020, International journal of cancer.

[20]  C. Sautès-Fridman,et al.  The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies , 2020, Frontiers in Immunology.

[21]  Jinsheng Hong,et al.  Prognostic Value of a Stemness Index-Associated Signature in Primary Lower-Grade Glioma , 2020, Frontiers in Genetics.

[22]  T. Baba,et al.  Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions , 2020, International journal of molecular sciences.

[23]  X. Gou,et al.  EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients , 2020, Aging.

[24]  A. Mantovani,et al.  Diversity, Mechanisms, and Significance of Macrophage Plasticity. , 2020, Annual review of pathology.

[25]  A. Menga,et al.  The Crowded Crosstalk between Cancer Cells and Stromal Microenvironment in Gynecological Malignancies: Biological Pathways and Therapeutic Implication , 2019, International journal of molecular sciences.

[26]  Lingli Chen,et al.  Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer , 2019, Gut.

[27]  Yingchun He,et al.  In silico analyses for potential key genes associated with gastric cancer , 2018, PeerJ.

[28]  M. Najafi,et al.  CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review , 2018, Journal of cellular physiology.

[29]  T. Bathen,et al.  Integrative metabolic and transcriptomic profiling of prostate cancer tissue containing reactive stroma , 2018, Scientific Reports.

[30]  X. Liu,et al.  Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response , 2018, Nature Medicine.

[31]  Joshua M. Stuart,et al.  Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. , 2018, Cell.

[32]  Steven J. M. Jones,et al.  The Immune Landscape of Cancer , 2018, Immunity.

[33]  N. Hiraoka,et al.  Tumor‐associated CD204+ M2 macrophages are unfavorable prognostic indicators in uterine cervical adenocarcinoma , 2018, Cancer science.

[34]  H. Clevers,et al.  Cancer stem cells revisited , 2017, Nature Medicine.

[35]  W. O'Neal,et al.  Membrane Mucin Muc4 Promotes Blood Cell Association with Tumor Cells and Mediates Efficient Metastasis in a Mouse Model of Breast Cancer , 2017, Oncogene.

[36]  X. Zuo,et al.  RNA editing of SLC22A3 drives early tumor invasion and metastasis in familial esophageal cancer , 2017, Proceedings of the National Academy of Sciences.

[37]  Siqi Bao,et al.  An Immune-Related Six-lncRNA Signature to Improve Prognosis Prediction of Glioblastoma Multiforme , 2017, Molecular Neurobiology.

[38]  E. Gomaa.  Antimicrobial, antioxidant and antitumor activities of silver nanoparticles synthesized by Allium cepa extract: A green approach , 2017, Journal, genetic engineering & biotechnology.

[39]  M. Ziemer,et al.  CPI-17 drives oncogenic Ras signaling in human melanomas via Ezrin-Radixin-Moesin family proteins , 2016, Oncotarget.

[40]  M. Dhodapkar,et al.  Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. , 2015, Blood.

[41]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[42]  N. Hacohen,et al.  Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.

[43]  Paul Geeleher,et al.  pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression Levels , 2014, PloS one.

[44]  Jean-François Dartigues,et al.  Estimating and comparing time‐dependent areas under receiver operating characteristic curves for censored event times with competing risks , 2013, Statistics in medicine.

[45]  G. Getz,et al.  Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.

[46]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[47]  Guangchuang Yu,et al.  clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.

[48]  Trevor Hastie,et al.  Regularization Paths for Cox's Proportional Hazards Model via Coordinate Descent. , 2011, Journal of statistical software.

[49]  G. Rashid,et al.  The synthetic estrogen diethylstilbestrol (DES) inhibits the telomerase activity and gene expression of prostate cancer cells , 2010, The Prostate.

[50]  Matthew D. Wilkerson,et al.  ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking , 2010, Bioinform..

[51]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[52]  Gerhard Christofori,et al.  Distinct mechanisms of tumor invasion and metastasis. , 2007, Trends in molecular medicine.

[53]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.